Shanghai MicuRx Pharmaceutical Co. Ltd. A (688373.SS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE100005PX4

Price
5.04 CNY
Market cap
3.30 bn CNY
P/E (2025)
–
P/S (2025)
23.31
Dividend yield
0.00 %
Net margin
-170.42 %
Return on equity (ROE)
-117.55 %
Return on assets (ROA)
-34.27 %

Shanghai MicuRx Pharmaceutical Co. Ltd. A financials

Fiscal year20242025
Revenue130.27 m CNY141.77 m CNY
Gross profit107.87 m CNY120.24 m CNY
Operating income-436.53 m CNY-244.30 m CNY
EBIT-423.36 m CNY-232.67 m CNY
Net income-440.72 m CNY-241.61 m CNY
Diluted EPS – continuing operations-0.67 CNY-0.37 CNY

Full history since 2020, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Shanghai MicuRx Pharmaceutical Co. Ltd. A

Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment of COVID-19; and MRX-23 for the treatment of tumour. The company was founded in 2007 and is based in Shanghai, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.